ArticleGynecologic oncology reports2026
Systemic inflammation indices and serum squamous cell carcinoma (SCC) antigen: an exploratory analysis on prognosis of patients with vulvar squamous cell carcinoma.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab-Lenvatinib: A Retrospective Real-World Study.Current oncology (Toronto, Ont.) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the relationship between hematologic inflammatory indices, serum squamous cell carcinoma antigen (SCC-Ag), and clinicopathological features in vulvar squamous cell carcinoma (VSCC). Methods: Twenty-seven women with primary VSCC were prospectively analyzed. Peripheral leukocyte subsets and derived ratios, including neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and eosinophil-to-lymphocyte ratio (ELR), were assessed preoperatively. SCC-Ag was measured in 16 patients and analyzed using a 1.9 ng/mL cut-off. Associations with tumor grade, recurrence, and mortality were investigated through non-parametric tests and ROC analysis. Results: Patients with SCC-Ag ≥ 1.9 ng/mL showed significantly lower lymphocyte counts (1.66 vs. 2.41 × 10 Conclusions: Elevated SCC-Ag levels in VSCC are associated with lymphopenia and poor tumor differentiation, reflecting an unfavorable systemic immune profile. The combination of SCC-Ag and inflammatory indices, particularly NLR, may offer a simple and cost-effective tool for postoperative prognostic assessment and surveillance planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.